as 08-08-2025 10:42am EST
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Founded: | 1994 | Country: | France |
Employees: | N/A | City: | N/A |
Market Cap: | 116.5B | IPO Year: | N/A |
Target Price: | $65.00 | AVG Volume (30 days): | 2.3M |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | Dividend Payout Frequency: | Annual | |
EPS: | 8.65 | EPS Growth: | 118.56 |
52 Week Low/High: | $44.73 - $60.12 | Next Earning Date: | 07-31-2025 |
Revenue: | $53,714,621,258 | Revenue Growth: | 15.65% |
Revenue Growth (this year): | 2.85% | Revenue Growth (next year): | 6.65% |
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 hours ago
GlobeNewswire
5 hours ago
Zacks
a day ago
GlobeNewswire
a day ago
GlobeNewswire
a day ago
Pharmaceutical Technology
a day ago
GlobeNewswire
a day ago
Argus Research
a day ago
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.